SCHEMBL285141

SCHEMBL285141

CC(=O)OC(=O)c1ccccc1O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.64
TSHR P16473 2/20 0.64
HPGD P15428 7/20 0.55
HSD17B10 Q99714 4/20 0.55
ALOX15 P16050 2/20 0.55
TDP1 Q9NUW8 2/20 0.53
ALDH1A1 P00352 6/20 0.50
KDM4E B2RXH2 5/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
HMGB1 P09429 1/20 0.50
CA4 P22748 1/20 0.50
CA6 P23280 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50
NAPRT Q6XQN6 1/20 0.50
CA14 Q9ULX7 1/20 0.50
MAPT P10636 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13570450 0.98 TSHR (0.62) LMNATSHRHPGDHSD17B10ALOX15
SCHEMBL6245920 0.98 LMNA (0.62) LMNATSHRHPGDHSD17B10ALOX15
SCHEMBL9636052 0.98 LMNA (0.62) LMNATSHRHPGDHSD17B10ALOX15
SCHEMBL7761655 0.98 LMNA (0.62) LMNATSHRHPGDHSD17B10ALOX15
SCHEMBL162390 0.98 LMNA (0.62) LMNATSHRHPGDHSD17B10ALOX15
Hydrochloric Acid SCHEMBL11262444 0.98 LMNA (0.62) LMNATSHRHPGDHSD17B10ALOX15
SCHEMBL7761593 0.98 LMNA (0.62) LMNATSHRHPGDHSD17B10ALOX15
SCHEMBL11337153 0.98 LMNA (0.62) LMNATSHRHPGDHSD17B10ALOX15
SCHEMBL9636042 0.98 LMNA (0.62) LMNATSHRHPGDHSD17B10ALOX15
SCHEMBL28461971 0.98 LMNA (0.62) LMNATSHRHPGDHSD17B10ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1020 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250025426-A1 SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE SUBSTANCES IN NANOPARTICLES Karlsruher Institut für Technologie (DE) 2025-01-23 US claimed
CN-116999360-A Anti-aging cosmetic and preparation method thereof 上海普瑞康企业发展有限公司 2023-11-07 CN claimed
CN-116437947-A Non-pig formulations and methods thereof 第一浪潮生物制药有限公司 2023-07-14 CN claimed
US-11478467-B2 Targeted drug rescue with novel compositions, combinations, and methods thereof Exciva GmbH (DE) 2022-10-25 US claimed
US-20220296586-A1 NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF Vepachedu, Sreenivasarao (US) 2022-09-22 US claimed
US-20220218725-A1 METHODS AND MATERIALS FOR TREATING CANCER MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2022-07-14 US claimed
EP-3968987-A1 METHODS AND MATERIALS FOR TREATING CANCER Mayo Foundation for Medical Education and Research (US) 2022-03-23 EP claimed
US-20210330733-A1 TOPICAL COMPOSITION FOR PAIN RELIEF FULADI BOB (US) 2021-10-28 US claimed
WO-2021086964-A1 METHODS OF USING CANNABINOID COMPOSITIONS IN SPORTS MEDICINE APPLICATIONS Precision Biologics (US) 2021-05-06 WO claimed
WO-2020232439-A1 METHODS AND MATERIALS FOR TREATING CANCER MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2020-11-19 WO claimed
EP-0169465-B1 MIXTURE OF PYRIMIDO-PYRIMIDINES AND O-ACETYL-SALICYLIC ACID, OR THEIR PHARMACOLOGICALLY ACCEPTABLE SALTS, AND ITS USE HOECHST AKTIENGESELLSCHAFT (DE) 1990-02-28 EP claimed
US-4880791-A BLOOD DISORDERS HOECHST AKTIENGESELLSCHAFT (DE) 1989-11-14 US claimed
US-4850489-A Dispensing packs containing pharmaceutical combinations for sequential administration HOECHST AKTIENGESELLSCHAFT (DE) 1989-07-25 US claimed
EP-0292435-A1 Zea mays plants and transgenic zea mays plants regenerated from protoplasts or protoplast-derived cells CIBA-GEIGY AG (CH) 1988-11-23 EP claimed
US-4694024-A ANTICOAGULANT MIXTURE HOECHST AKTIENGESELLSCHAFT (DE) 1987-09-15 US claimed
EP-0089857-B1 PHARMACEUTICAL COMPOUNDS AND PROCESS FOR THE MANUFACTURE OF SAME R.P. SCHERER CORPORATION (US) 1986-01-22 EP claimed
EP-0010061-B1 PHARMACEUTICAL PREPARATIONS CONTAINING A MOLLUSC EXTRACT Mc Farlane, Stuart John (NZ) 1983-07-13 EP claimed
US-4340679-A Culture media for inactivation of bacterial growth inhibitors ABBOTT LABORATORIES (US) 1982-07-20 US claimed
WO-1980000661-A1 PHARMACEUTICAL PREPARATIONS CROFT J (NZ) 1980-04-17 WO claimed
US-4003999-A MIXING ASPIRIN, TEA, AND A BASE TO FORM SOLUBLE ACETYL SALICYLATE; ACIDIFICATION A. H. ROBINS COMPANY, INCORPORATED (US) 1977-01-18 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11478467-B2 Targeted drug rescue with novel compositions, combinations, and methods thereof HTR2A, HTR2C, CYP3A43 LMNA 1421/4885TSHR 1153/4885HPGD 517/4885
US-20220218725-A1 METHODS AND MATERIALS FOR TREATING CANCER DDX21, LMNB1, XPOT LMNA 178/4885TSHR 4386/4885HPGD 2330/4885
US-20220296586-A1 NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF CYP2D6, HTR2A, CYP3A43 LMNA 2968/4885TSHR 1552/4885HPGD 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.